DrÀgerwerk stock: Berenberg keeps Buy rating, sets EUR 156 target
Published on 11/20/2026 at 17:16 | Editorial responsibility: Rafael MĂŒller, Editor-in-Chief AD HOC NEWSAnalyst view meets long-term targets
- Berenberg maintained its Buy recommendation after changing its price target.
- DrÀger's Ambition 2030 targets EUR 4.5 billion in sales and a 10%-12% EBIT margin.
- Medical and Safety are each expected to contribute EUR 500 million of additional sales by 2030.
On Friday, November 20, Berenberg kept its Buy rating on DrĂ€gerwerk and changed its price target from EUR 162 to EUR 156. The analyst action followed the company's Ambition 2030 presentation in LĂŒbeck on November 18, giving investors a fresh reference point for the strategy's execution.
DrÀgerwerk stock traded at EUR 116.60 on Xetra at 16:56 CET on Friday, November 20, 0.52 percent above the Xetra close of Thursday, November 19. The latest Berenberg target remains above that market price, although the change in the target itself is not a higher target numerically.
Targets set the execution test
DrÀger's plan calls for net sales of EUR 4.5 billion by 2030, up EUR 1 billion from 2025. The company expects Medical and Safety to contribute EUR 500 million each to the increase. Group EBIT margin is targeted at 10% to 12%, compared with 6.7% in 2025.
Medical is targeting EUR 2.5 billion in sales and a 7% to 9% EBIT margin by 2030. Safety is targeting EUR 2.0 billion in sales and a 14% to 16% EBIT margin. The company links the plan to integrated solutions, recurring revenue, selected growth markets, pricing, direct-cost optimization and productivity gains.
The targets are from DrÀgerwerk's Ambition 2030 announcement published by MarketScreener from EQS. Berenberg's rating and target change were reported by MarketScreener on November 20.
What investors watch next
The next quarterly results will show whether sales growth, margin improvement and productivity advances are developing in line with the long-term plan. The unchanged Buy recommendation leaves execution as the central issue behind Berenberg's valuation view.
German equities remain a reference point for investors following DrÀgerwerk: Current market reports.
More news and analyses on DrÀgerwerk stock.
DrÀgerwerk AG & Co. KGaA
- ISIN: DE0005550636
- WKN: 555063
- Ticker: DRW3
- Sector: Advanced Medical Equipment & Technology
- Price: EUR 116.60 on Xetra at 16:56 CET, Friday, November 20, 2026
- Change: 0.52 percent above the Xetra close of Thursday, November 19, 2026
- Xetra close: EUR 116.00 on Thursday, November 19, 2026
- 52-week range: EUR 66.00 to EUR 125.40
